53 A compound that reverses the molecular cause of cataract formation improves eye lens transparency in mice.
http://www.sciencemag.org/content/350/6261/674.abstract
52 Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00345-1/abstract
51 The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.
http://stm.sciencemag.org/content/7/309/309ra165
50 Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site.
http://www.sciencedirect.com/science/article/pii/S1074761315003039
49 A short N-terminal domain of HDAC4 preserves photoreceptors and restores visual function in retinitis pigmentosa.
http://www.nature.com/ncomms/2015/150814/ncomms9005/full/ncomms9005.html
48 Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury.
http://stm.sciencemag.org/content/7/297/297ra116
47 Plasticity of the human visual system after retinal gene therapy in patients with Leber’s congenital amaurosis.
http://stm.sciencemag.org/content/7/296/296ra110
46 Regulation of age-related macular degeneration-like pathology by complement factor H.
http://www.pnas.org/content/112/23/E3040.abstract
45 Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy.
http://www.pnas.org/content/112/23/E3030.abstract
44 Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy.
http://www.pnas.org/content/112/23/E3030
43 Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes.
http://www.nejm.org/doi/full/10.1056/NEJMoa1409463
42 Rod-Derived Cone Viability Factor Promotes Cone Survival by Stimulating Aerobic Glycolysis.
http://www.cell.com/cell/abstract/S0092-8674(15)00310-4
41 Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema.
http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
40 Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179.
http://www.nature.com/ncomms/2015/150123/ncomms7006/full/ncomms7006.html
39 Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness.
http://www.nature.com/ncomms/2015/150109/ncomms6614/full/ncomms6614.html
38 White matter changes linked to visual recovery after nerve decompression.
http://stm.sciencemag.org/content/6/266/266ra173
37 Human limbal biopsy–derived stromal stem cells prevent corneal scarring.
http://stm.sciencemag.org/content/6/266/266ra172
36 Brain–machine interface for eye movements.
http://www.pnas.org/content/111/49/17630.abstract
35 Blocking PirB up-regulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia.
http://stm.sciencemag.org/content/6/258/258ra140.abstract
34 Human stem cell-derived retinal cells for macular diseases.
http://download.thelancet.com/flatcontentassets/pdfs/S0140673614613763.pdf
|
